Chemed Corp (CHE) Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Chemed Corporation operates through two primary segments: VITAS Healthcare (hospice care) and Roto-Rooter (plumbing, drain cleaning, and water restoration). The company reported 14,629,484 shares of common stock outstanding as of the period end.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Service Revenues and Sales | $646.9 million | $589.2 million |
| Net Income | $71.8 million | $65.0 million |
| Diluted EPS | $4.86 | $4.24 |
| Adjusted Net Income | $83.1 million | $79.8 million |
| Adjusted Diluted EPS | $5.63 | $5.20 |
| Adjusted EBITDA | $121.7 million | $114.6 million |
| Operating Cash Flow | $32.7 million | $84.5 million |
| Cash and Equivalents | $173.9 million | $313.4 million |
| Debt Covenants | Compliant | Compliant |
Liquidity: The company maintains a $450 million revolving credit facility with approximately $404.5 million available. There is no variable rate debt outstanding as of March 31, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 9.8% year-over-year. VITAS revenue grew 15.1% driven by an 11.9% increase in days-of-care and a 3.2% Medicare reimbursement rate increase. Roto-Rooter revenue grew 1.8%, with growth in excavation and water restoration offsetting declines in drain cleaning and plumbing.
- Profitability: Net income rose 10.4%. The effective tax rate increased to 25.0% from 23.0% in the prior year.
- Cash Flow: Operating cash flow decreased significantly by $51.8 million to $32.7 million. This was primarily due to a $72.8 million increase in accounts receivable (partially due to the reclassification of a $47 million OAS deposit) and a $20.4 million decline in accounts payable.
- Balance Sheet: Accounts receivable increased by $114.7 million, while "Other assets" decreased by $47.3 million, reflecting the reclassification of the Office of Audit Services (OAS) deposit from a long-term asset to accounts receivable following a favorable legal ruling.
Outlook, Risks, and Unusual Items
- Legal Resolution: A significant contingency was resolved in Q1 2025. An Administrative Law Judge ruled in favor of VITAS regarding a Medicare audit dispute, reducing a potential overpayment demand to a de minimis amount. The $50.3 million deposit held for this matter was refunded.
- Acquisitions: VITAS completed the acquisition of Covenant Care in April 2024, which contributed approximately $11.5–$12.5 million in revenue and $1.8–$2.0 million in net income to Q1 2025 results.
- Capital Allocation: The company repurchased 50,000 shares in Q1 2025 at a weighted average price of $595.15. $225.6 million remains authorized under the current repurchase plan. Dividends were increased to $0.50 per share from $0.40.
- Risks: Management highlighted risks related to potential tariffs on steel (Roto-Rooter) and pharmaceuticals (VITAS), which could increase costs. Additionally, the company faces ongoing regulatory scrutiny common to the hospice industry.
Investor Verification Checklist
- Accounts Receivable Quality: Verify the sustainability of the $114.7 million increase in receivables, noting the one-time reclassification of the OAS deposit versus organic growth.
- Cash Flow Volatility: Monitor the normalization of operating cash flows, which were depressed by working capital timing and the receivable reclassification.
- Regulatory Exposure: Review ongoing Medicare/Medicaid audit risks for the VITAS segment, despite the recent favorable ruling.
- Margin Pressure: Assess the impact of potential tariffs on input costs (steel, pharmaceuticals) and the ability to pass these costs to customers or patients.
- Non-GAAP Reconciliations: Review the reconciliation of Adjusted EBITDA and Adjusted Net Income to understand the impact of stock-based compensation and amortization of reacquired franchise agreements.